

GLAXOSMITHKLINE PLC

Form 6-K

April 27, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 27 April 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr Roger Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Transfer of 49,152 Ordinary Shares between accounts.
 - b) Nature of the transaction

No change in beneficial ownership.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	49,152
 - d) Aggregated information

Aggregated volume Price n/a (single transaction)
 - e) Date of the transaction

2018-04-26
 - f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr Roger Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted
 Ordinary shares of 25 pence
 each ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
- b) Nature of the transaction
 Transfer of 49,152 Ordinary
 Shares to spouse for nil
 consideration.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £0.00 49,152
- d) Aggregated information
 Aggregated volume Price
 n/a (single transaction)
- e) Date of the transaction
 2018-04-27
- f) Place of the transaction
 n/a

Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs Denise Connor
 PCA of Mr Roger Connor
- b) Position/status
 (President, Global
 Manufacturing & Supply)
- c) Initial notification/
 amendment
 Initial Notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted
 Ordinary shares of 25 pence
 each ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
- b) Nature of the transaction
 Receipt of 49,152 Ordinary
 Shares from spouse for nil
 consideration.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £0.00 49,152
- d) Aggregated information
 Aggregated volume Price
 n/a (single transaction)
- e) Date of the transaction
 2018-04-27

f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 27, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc